EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Ligand Pharmaceuticals Incorporated (LGND) had EBIT Margin of 23.20% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$59.67M |
|
$44.78M |
|
$2.99M |
|
$56.67M |
|
$45.82M |
|
$13.84M |
|
$42.94M |
|
$56.78M |
|
$34.72M |
|
$44.78M |
|
$44.78M |
|
$44.78M |
|
$18.67M |
|
$13.84M |
|
$20.61M |
|
19.34M |
|
20.29M |
|
$2.41 |
|
$2.42 |
|
| Balance Sheet Financials | |
$832.27M |
|
-- |
|
$728.37M |
|
$1.56B |
|
$37.45M |
|
$446.19M |
|
$505.98M |
|
$543.42M |
|
$1.02B |
|
$690.23M |
|
$1.02B |
|
19.77M |
|
| Cash Flow Statement Financials | |
$49.36M |
|
$-377.32M |
|
$428.22M |
|
$72.31M |
|
$174.93M |
|
$102.62M |
|
$46.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
22.23 |
|
-- |
|
-- |
|
0.30 |
|
0.44 |
|
94.99% |
|
23.20% |
|
|
EBIT Margin |
23.20% |
-- |
|
95.16% |
|
75.06% |
|
$38.05M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
0.33 |
|
0.98 |
|
92.08 |
|
4.40% |
|
6.49% |
|
2.87% |
|
3.06% |
|
$51.44 |
|
$1.87 |
|
$2.43 |
|